Now, test to predict aggressiveness of prostate cancerApril 20th, 2010 - 2:56 pm ICT by ANI
Washington, Apr 20 (ANI): Johns Hopkins boffins have evaluated a simple, more specific blood test that identifies patients undergoing proactive surveillance for low-grade, low-stage, non-palpable prostate cancer who would eventually require treatment.
The results, presented at the American Association for Cancer Research 101st Annual Meeting 2010, may be a major advance in prostate cancer risk assessment.
“Finding biomarkers that can predict future unfavorable biopsy conversion will help us to identify men with prostate cancer who may or may not need treatment,” said Robert W. Veltri, Ph.D., associate professor of urology and oncology and director of the Fisher Biorepository & Biomarker Laboratory at The Brady Urological Research Institute, Johns Hopkins Hospital, Baltimore.
Using the novel application of the Prostate Health Index immunoassay and DNA content measurements performed by image analysis, Veltri and colleagues tested 71 patients enrolled in the Johns Hopkins Hospital Proactive Surveillance Program.
The Prostate Health Index, developed by Beckman-Coulter, Inc., is a calculation involving at least three forms of free prostate-specific antigen (PSA), of which pro-PSA is one.
Thirty-nine patients developed an unfavorable biopsy, which is cancer progression defined as an increase in grade or tumor volume.
The remaining patients maintained favorable biopsies. Veltri and colleagues measured serum total PSA, free PSA and pro-PSA, performed a digital rectal examination semiannually and conducted a surveillance biopsy examination each year.
Results showed that the level of Prostate Health Index was higher in men who were determined to have unfavorable biopsies, according to Veltri.
In addition, the researchers found that DNA content in biopsy tissue from the prostate gland next to the cancer area and area itself were significant predictors of a change from a favorable to an unfavorable biopsy in the Proactive Surveillance patients.
“Our findings were slightly surprising; serum pro-PSA level by itself was not able to predict unfavorable biopsy conversion in our Proactive Surveillance Program,” Veltri said. “However, Prostate Health Index, which incorporates pro-PSA, free PSA and total PSA in the index, was significant for predicting unfavorable biopsy conversion.” (ANI)
- New test accurately detects aggressive prostate cancer - Apr 07, 2011
- New method detects aggressive prostate cancer - Aug 09, 2012
- Change in PSA level poor predictor of prostate cancer - Feb 25, 2011
- Dogs can 'sniff out' prostate cancer accurately from urine sample - Feb 08, 2011
- Men with long ring finger 'three times more likely to get prostate cancer' - Jul 21, 2010
- New ultrasound technology can accurately spot prostate cancer tumours - Dec 09, 2010
- Heart disease may be linked to prostate cancer - Feb 09, 2012
- MRI can help locate prostate cancer recurrence at extremely low PSA levels - Apr 30, 2011
- Hidden prostate cancer tumours evade treatment: study - Oct 09, 2009
- Robot-assisted surgery to remove cancerous prostate glands is safe - Mar 24, 2011
- Most men unaware of blood test for prostate cancer, finds charity - Mar 01, 2011
- Potent anticancer drug isolated from weed - Jul 10, 2012
- PSA test more reliable in men taking prostate-shrinking drug - Dec 18, 2010
- Dense bones associated with raised risk for prostate cancer - Jul 29, 2010
- Heart drug cuts prostate cancer risk - Apr 03, 2011
Tags: beckman coulter, beckman coulter inc, boffins, cancer progression, cancer risk assessment, digital rectal examination, dna content, free psa, health index, johns hopkins hospital, johns hopkins hospital baltimore, novel application, prostate cancer, prostate cancer risk, prostate specific antigen, psa free, surveillance program, tumor volume, urological research, veltri